Swift Biosciences said this week that Steve Spotts has joined the company as chief commercial officer.
Prior to joining Swift, Spotts was commercial modality leader for label-free products at GE Healthcare. Prior to that, he was vice president of sales and marketing at MicroCal. Spotts has also served as vice president of sales and marketing, and vice president of marketing at Pharmacia Biotech (now GE Healthcare); and as a management consultant to the life science industry.
Spotts holds an MBA from Loyola College; a BS in biology from Dickinson College; and an MS in biology from Shippensburg State College.
Integrated Diagnostics said this week that Jay Moyes has joined the company as an independent director.
Moyes has served as chief financial officer at several companies, including XDx, Myriad Genetics, and Genmark. Prior to that, he worked for international public accounting firm KPMG. He currently serves as director and chair of the audit committees of both Osiris Therapeutics and BioCardia.
Qiagen said this week that Vera Kallmeyer and Elizabeth Tallett have been proposed for election to Qiagen's supervisory board.
Kallmeyer is consulting professor in the Department of Neurosurgery at Stanford School of Medicine, and is the founder and managing partner of financial advisory and investment firm Equity4Health. She was also formerly chief financial officer and vice president of corporate development at Aviron, now part of MedImmune/AstraZeneca.
Tallett has served as president and CEO of Transcell Technologies, president of Centocor Pharmaceuticals, a member of the Parke-Davis executive committee, and director of worldwide strategic planning for Warner-Lambert.
Shareholders will vote to elect Kallmeyer and Tallett at the next annual general meeting scheduled for June 30.